Drug,Chemical Structure,Adverse Effect / Toxicity,Species,Dose,Dose Type,Route,Source,Source Link,Year,no_stereoisomer
Abemaciclib,CCN1CCN(CC1)CC1=CC=C(NC2=NC=C(F)C(=N2)C2=CC3=C(N=C(C)N3C(C)C)C(F)=C2)N=C1,Hepatic steatosis,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 208716/S-000 Part 09, page:15 PDF 678k",https://www.pharmapendium.com/browse/fda/Abemaciclib/a50315d3a726a8049e1d15f32cd253cf?reference=15,2017.0,CCN1CCN(CC1)CC1=CC=C(NC2=NC=C(F)C(=N2)C2=CC3=C(N=C(C)N3C(C)C)C(F)=C2)N=C1
Acitretin,COC1=CC(C)=C(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)C(C)=C1C,Hepatic steatosis,Human,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Approval Package 019821 Part 01, page:13 PDF 7773k",https://www.pharmapendium.com/browse/fda/Acitretin/1a0cb7a639fe6c5d73334f9d95bc1bc6?reference=13,1996.0,COC1=CC(C)=C(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)C(C)=C1C
Adefovir Dipivoxil,CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C1N=CN=C2N)OCOC(=O)C(C)(C)C,Hepatic steatosis,Human,-1.0,Repeated,Oral,"EMA approval document: ANNEX I, page:5 PDF 557k",https://www.pharmapendium.com/browse/ema/Adefovir Dipivoxil/2e1895c9ecb48f44229ee0cad2869763?reference=5,2019.0,CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C1N=CN=C2N)OCOC(=O)C(C)(C)C
Cabotegravir Sodium,[H][C@@]12CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)C([O-])=C3C(=O)N1[C@@H](C)CO2,Hepatic steatosis,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Review 212887/S-000; 212888/S-000 Part 19, page:9 PDF 701k",https://www.pharmapendium.com/browse/fda/Cabotegravir Sodium/d8a48ae1e91b38d344fc32218cf5483b?reference=9,2019.0,[H][C]12CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)C([O-])=C3C(=O)N1[CH](C)CO2
Cenobamate,NC(=O)O[C@@H](CN1N=CN=N1)C1=CC=CC=C1Cl,Hepatic steatosis,Human,-2.3979400086720375,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 212839/S-000 Part 15, page:39 PDF 1604k",https://www.pharmapendium.com/browse/fda/Cenobamate/d41c102f04e6df0797332bbe00aa2289?reference=39,2019.0,NC(=O)O[CH](CN1N=CN=N1)C1=CC=CC=C1Cl
Clozapine,CN1CCN(CC1)C1=NC2=C(NC3=C1C=CC=C3)C=CC(Cl)=C2,Hepatic steatosis,Human,-2.9542425094393248,Repeated,Oral,"FDA approval package document: Label 203479/S-000, page:27 PDF 1267k",https://www.pharmapendium.com/browse/fda/Clozapine/107c277867a1040822f8ad90fa780b3d?reference=27,2013.0,CN1CCN(CC1)C1=NC2=C(NC3=C1C=CC=C3)C=CC(Cl)=C2
Cobicistat,CC(C)C1=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)CC2=CC=CC=C2)=CS1,Hepatic steatosis,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 203094/S-000 Part 05, page:75 PDF 15871k",https://www.pharmapendium.com/browse/fda/Cobicistat/cf97ec370dc39aa6baa9336ae252e4c6?reference=75,2012.0,CC(C)C1=NC(CN(C)C(=O)N[CH](CCN2CCOCC2)C(=O)N[CH](CC[CH](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)CC2=CC=CC=C2)=CS1
Darunavir Ethanolate,[H][C@]12OCC[C@@]1([H])[C@H](CO2)OC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1,Hepatic steatosis,Human,-2.9030899869919438,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/304651/2012; EMEA/H/C/000707/X/0041/G, page:31 PDF 374k",https://www.pharmapendium.com/browse/ema/Darunavir Ethanolate/6cd5c78c0742d1e6d915c9e0a0c885f4?reference=31,2012.0,[H][C]12OCC[C]1([H])[CH](CO2)OC(=O)N[CH](CC1=CC=CC=C1)[CH](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1
Deferasirox,OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O,Hepatic steatosis,Human,-1.4771212547196624,Repeated,Oral,"EMA approval document: Scientific Discussion, page:36 PDF 564k",https://www.pharmapendium.com/browse/ema/Deferasirox/aead5c74d6060f6540c15dd3aeb9791f?reference=36,2006.0,OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O
Diazepam,CN1C(=O)CN=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C12,Hepatic steatosis,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Approval Package 013263/S-003, S-008, S-019, S-040, S-041, S-042, S-043, S-046, S-049, S-054; 016087/S-040, S-042, S-045; 017984/S-010; 018179/S-001 Part 01, page:51 PDF 4467k",https://www.pharmapendium.com/browse/fda/Diazepam/c07af973f7b6af41e0a0b1e6c18fe979?reference=51,1963.0,CN1C(=O)CN=C(C2=CC=CC=C2)C2=CC(Cl)=CC=C12
Dolutegravir Sodium,[H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C([O-])=C3C(=O)N1[C@H](C)CCO2,Hepatic steatosis,Human,-2.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 204790 Part 04, page:26 PDF 7848k",https://www.pharmapendium.com/browse/fda/Dolutegravir Sodium/1ad0a2b9727ce58261902f144c3cb335?reference=26,2012.0,[H][C]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C([O-])=C3C(=O)N1[CH](C)CCO2
Duloxetine Hydrochloride,CNCC[C@H](OC1=C2C=CC=CC2=CC=C1)C1=CC=CS1,Hepatic steatosis,Human,-2.0791812460476247,Repeated,Oral,"FDA approval package document: Label 021427/S-012; 021520/S-011; 021235/S-007; 020974/S-008; 020101/S-035; 018936/S-076, page:92 PDF 964k",https://www.pharmapendium.com/browse/fda/Duloxetine Hydrochloride/3b69d8bbe852a64df615fb05309f07c6?reference=92,2006.0,CNCC[CH](OC1=C2C=CC=CC2=CC=C1)C1=CC=CS1
Empagliflozin,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC(CC2=CC=C(O[C@H]3CCOC3)C=C2)=C(Cl)C=C1,Hepatic steatosis,Human,-1.3979400086720377,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/137741/2014; EMEA/H/C/002677/0000, page:77 PDF 1395k",https://www.pharmapendium.com/browse/ema/Empagliflozin/436354e1f4b6b84ebc2d059cab3caf56?reference=77,2014.0,OC[CH]1O[CH]([CH](O)[CH](O)[CH]1O)C1=CC(CC2=CC=C(O[CH]3CCOC3)C=C2)=C(Cl)C=C1
Emtricitabine,NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1,Hepatic steatosis,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Label 021500/S-003, page:9 PDF 422k",https://www.pharmapendium.com/browse/fda/Emtricitabine/ec1c7a72b306942b3121d9035f68f912?reference=9,2005.0,NC1=NC(=O)N(C=C1F)[CH]1CS[CH](CO)O1
Enfuvirtide,CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O,Hepatic steatosis,Human,-1.954242509439325,Repeated,Subcutaneous,"FDA approval package document: Medical/Clinical Review 021481/S-000 Part 03, page:15 PDF 1579k",https://www.pharmapendium.com/browse/fda/Enfuvirtide/9c859d46bfd410da3c7c3fe0f16ead14?reference=15,2003.0,CC[CH](C)[CH](NC(=O)[CH](CC(C)C)NC(=O)[CH](CO)NC(=O)[CH](CC1=CNC=N1)NC(=O)[CH](NC(=O)[CH](CC(C)C)NC(=O)[CH](CO)NC(=O)[CH](NC(=O)[CH](CC1=CC=C(O)C=C1)NC(C)=O)[CH](C)O)[CH](C)CC)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CO)C(=O)N[CH](CCC(N)=O)C(=O)N[CH](CC(N)=O)C(=O)N[CH](CCC(N)=O)C(=O)N[CH](CCC(N)=O)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CCCCN)C(=O)N[CH](CC(N)=O)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CCC(N)=O)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CC(C)C)C(=O)N[CH](CC(C)C)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CC(C)C)C(=O)N[CH](CC(O)=O)C(=O)N[CH](CCCCN)C(=O)N[CH](CC1=CNC2=CC=CC=C12)C(=O)N[CH](C)C(=O)N[CH](CO)C(=O)N[CH](CC(C)C)C(=O)N[CH](CC1=CNC2=CC=CC=C12)C(=O)N[CH](CC(N)=O)C(=O)N[CH](CC1=CNC2=CC=CC=C12)C(=O)N[CH](CC1=CC=CC=C1)C(N)=O
Entecavir,NC1=NC2=C(N=CN2[C@H]2C[C@H](O)[C@@H](CO)C2=C)C(=O)N1,Hepatic steatosis,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021797/S-000, page:99 PDF 6640k",https://www.pharmapendium.com/browse/fda/Entecavir/4e8b214a689c08907da074b52f3b58a4?reference=99,2005.0,NC1=NC2=C(N=CN2[CH]2C[CH](O)[CH](CO)C2=C)C(=O)N1
Eslicarbazepine Acetate,CC(=O)O[C@H]1CC2=C(C=CC=C2)N(C(N)=O)C2=C1C=CC=C2,Hepatic steatosis,Human,-2.9542425094393248,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022416/S-000 Part 32, page:5 PDF 3195k",https://www.pharmapendium.com/browse/fda/Eslicarbazepine Acetate/f2d85852b29e4b93519f0aa1431fd325?reference=5,2013.0,CC(=O)O[CH]1CC2=C(C=CC=C2)N(C(N)=O)C2=C1C=CC=C2
Etravirine,CC1=CC(=CC(C)=C1OC1=NC(NC2=CC=C(C=C2)C#N)=NC(N)=C1Br)C#N,Hepatic steatosis,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Label 022187/S-000, page:4 PDF 627k",https://www.pharmapendium.com/browse/fda/Etravirine/f3b75529b34b132b9caa21156867fa4e?reference=4,2008.0,CC1=CC(=CC(C)=C1OC1=NC(NC2=CC=C(C=C2)C#N)=NC(N)=C1Br)C#N
Febuxostat,CC(C)COC1=CC=C(C=C1C#N)C1=NC(C)=C(S1)C(O)=O,Hepatic steatosis,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Label 021856/S-000, page:4 PDF 329k",https://www.pharmapendium.com/browse/fda/Febuxostat/cb2dd76be1473b65cae6848e33169719?reference=4,2009.0,CC(C)COC1=CC=C(C=C1C#N)C1=NC(C)=C(S1)C(O)=O
Fingolimod Hydrochloride,CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1,Hepatic steatosis,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022527/S-000 Part 13, page:3 PDF 559k",https://www.pharmapendium.com/browse/fda/Fingolimod Hydrochloride/defc16f7a20b3608da55dfb4be34f3c9?reference=3,2009.0,CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1
Fluoxetine Hydrochloride,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1,Hepatic steatosis,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Label 021860/S-000, page:17 PDF 396k",https://www.pharmapendium.com/browse/fda/Fluoxetine Hydrochloride/2cf746d62681e1c36fa43d4fa430d1e7?reference=17,2005.0,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
Fluvastatin Sodium,CC(C)N1C2=CC=CC=C2C(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O,Hepatic steatosis,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 020261/S-046 Part 03, page:14 PDF 808k",https://www.pharmapendium.com/browse/fda/Fluvastatin Sodium/4845d89ec455c3d165fc7e5de2f27555?reference=14,2012.0,CC(C)N1C2=CC=CC=C2C(C2=CC=C(F)C=C2)=C1\C=C\[CH](O)C[CH](O)CC([O-])=O
Ketoprofen,CC(C(O)=O)C1=CC=CC(=C1)C(=O)C1=CC=CC=C1,Hepatic steatosis,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 019816/S-001, S-002 Part 09, page:35 PDF 4729k",https://www.pharmapendium.com/browse/fda/Ketoprofen/7c397d32cb867f8f0414b6db39cc368c?reference=35,1993.0,CC(C(O)=O)C1=CC=CC(=C1)C(=O)C1=CC=CC=C1
Lamivudine,NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1,Hepatic steatosis,Human,-2.4771212547196626,Repeated,Oral,"EMA approval document: Scientific Discussion, page:14 PDF 229k",https://www.pharmapendium.com/browse/ema/Lamivudine/015492768804d3ae3c08845b0b8ea92f?reference=14,2005.0,NC1=NC(=O)N(C=C1)[CH]1CS[CH](CO)O1
Lasofoxifene,OC1=CC=C2[C@H]([C@H](CCC2=C1)C1=CC=CC=C1)C1=CC=C(OCCN2CCCC2)C=C1,Hepatic steatosis,Human,-0.6989700043360189,Repeated,Oral,"EMA approval document: ANNEX I, page:7 PDF 474k",https://www.pharmapendium.com/browse/ema/Lasofoxifene/4a30d26487d86d298e55209f18660544?reference=7,2013.0,OC1=CC=C2[CH]([CH](CCC2=C1)C1=CC=CC=C1)C1=CC=C(OCCN2CCCC2)C=C1
Lesinurad,OC(=O)CSC1=NN=C(Br)N1C1=C2C=CC=CC2=C(C=C1)C1CC1,Hepatic steatosis,Human,-2.6020599913279625,Repeated,Oral,"EMA approval document: Assessment Report EMA/6459/2016; EMEA/H/C/003932/0000, page:110 PDF 5667k",https://www.pharmapendium.com/browse/ema/Lesinurad/d22d8c9f5d65c0aae620ada4cabc6eaa?reference=110,2015.0,OC(=O)CSC1=NN=C(Br)N1C1=C2C=CC=CC2=C(C=C1)C1CC1
Levofloxacin,C[C@H]1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O,Hepatic steatosis,Human,-2.380211241711606,Repeated,Inhalation,"EMA approval document: Assessment Report EMA/CHMP/676680/2014; EMEA/H/C/002789/0000, page:89 PDF 2953k",https://www.pharmapendium.com/browse/ema/Levofloxacin/2191eac850f7b5fc0a4f9614accec6cd?reference=89,2014.0,C[CH]1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O
Linagliptin,CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=CC=CC=C3C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1,Hepatic steatosis,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 201280/S-000 Part 04, page:98 PDF 5485k",https://www.pharmapendium.com/browse/fda/Linagliptin/4040600348d5f8e24c3f5c858638a448?reference=98,2010.0,CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=CC=CC=C3C(C)=N1)C(=O)N2C)N1CCC[CH](N)C1
Liraglutide,CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CN=CN1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O,Hepatic steatosis,Human,-0.9030899869919435,Repeated,Subcutaneous,"FDA approval package document: Approval Package 022341/S-027 Part 23, page:46 PDF 9721k",https://www.pharmapendium.com/browse/fda/Liraglutide/b5167110732dfcd7a8cc0c3da576ecf4?reference=46,2016.0,CCCCCCCCCCCCCCCC(=O)N[CH](CCC(=O)NCCCC[CH](NC(=O)[CH](C)NC(=O)[CH](C)NC(=O)[CH](CCC(N)=O)NC(=O)CNC(=O)[CH](CCC(O)=O)NC(=O)[CH](CC(C)C)NC(=O)[CH](CC1=CC=C(O)C=C1)NC(=O)[CH](CO)NC(=O)[CH](CO)NC(=O)[CH](NC(=O)[CH](CC(O)=O)NC(=O)[CH](CO)NC(=O)[CH](NC(=O)[CH](CC1=CC=CC=C1)NC(=O)[CH](NC(=O)CNC(=O)[CH](CCC(O)=O)NC(=O)[CH](C)NC(=O)[CH](N)CC1=CN=CN1)[CH](C)O)[CH](C)O)C(C)C)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CC1=CC=CC=C1)C(=O)N[CH]([CH](C)CC)C(=O)N[CH](C)C(=O)N[CH](CC1=CNC2=C1C=CC=C2)C(=O)N[CH](CC(C)C)C(=O)N[CH](C(C)C)C(=O)N[CH](CCCNC(N)=N)C(=O)NCC(=O)N[CH](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O
Lorlatinib,C[C@H]1OC2=CC(=CN=C2N)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=C1C=C(F)C=C2,Hepatic steatosis,Human,-2.0,Repeated,Oral,"FDA approval package document: Approval Package 210868/S-000 Part 09, page:57 PDF 1228k",https://www.pharmapendium.com/browse/fda/Lorlatinib/bd3ecb44dfc93ea65ade6b9e1d3ea355?reference=57,2018.0,C[CH]1OC2=CC(=CN=C2N)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=C1C=C(F)C=C2
Methylphenidate Hydrochloride,COC(=O)C(C1CCCCN1)C1=CC=CC=C1,Hepatic steatosis,Human,-1.7323937598229686,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021121/S-008, page:7 PDF 3054k",https://www.pharmapendium.com/browse/fda/Methylphenidate Hydrochloride/65f65d8be767721bf087630ec070a5ca?reference=7,2004.0,COC(=O)C(C1CCCCN1)C1=CC=CC=C1
Micafungin Sodium,[H][C@@]12C[C@@H](O)CN1C(=O)[C@@H](NC(=O)[C@H](C[C@@H](O)[C@@H](O)NC(=O)[C@]1([H])[C@@H](O)[C@@H](C)CN1C(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@H](O)[C@@H](O)C1=CC=C(O)C(OS([O-])(=O)=O)=C1)[C@H](O)CC(N)=O)NC(=O)C1=CC=C(C=C1)C1=NOC(=C1)C1=CC=C(OCCCCC)C=C1)[C@@H](C)O,Hepatic steatosis,Human,-2.1760912590556813,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 021754/S-000 Part 03, page:6 PDF 7132k",https://www.pharmapendium.com/browse/fda/Micafungin Sodium/0e7d32ac0bd233b9c781a736663a1981?reference=6,2005.0,[H][C]12C[CH](O)CN1C(=O)[CH](NC(=O)[CH](C[CH](O)[CH](O)NC(=O)[C]1([H])[CH](O)[CH](C)CN1C(=O)[CH](NC(=O)[CH](NC2=O)[CH](O)[CH](O)C1=CC=C(O)C(OS([O-])(=O)=O)=C1)[CH](O)CC(N)=O)NC(=O)C1=CC=C(C=C1)C1=NOC(=C1)C1=CC=C(OCCCCC)C=C1)[CH](C)O
Milnacipran Hydrochloride,CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)C1=CC=CC=C1,Hepatic steatosis,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022256/S-000 Part 02, page:30 PDF 6827k",https://www.pharmapendium.com/browse/fda/Milnacipran Hydrochloride/4c84f50c0997fbb4cfe3c70b7e24504a?reference=30,2008.0,CCN(CC)C(=O)[C]1(C[CH]1CN)C1=CC=CC=C1
Nifurtimox,CC1CS(=O)(=O)CCN1\N=C\C1=CC=C(O1)N(=O)=O,Hepatic steatosis,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 213464/S-000 Part 11, page:16 PDF 1328k",https://www.pharmapendium.com/browse/fda/Nifurtimox/e9d4eb0685abf6ace1b8ed30e239e58d?reference=16,2020.0,CC1CS(=O)(=O)CCN1\N=C\C1=CC=C(O1)N(=O)=O
Nizatidine,CN\C(NCCSCC1=CSC(CN(C)C)=N1)=C\N(=O)=O,Hepatic steatosis,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Approval Package 019508/S-012, S-016, S-012, S-013 Part 05, page:15 PDF 7677k",https://www.pharmapendium.com/browse/fda/Nizatidine/1cb2680c26165bb3235acb6c5a56a5db?reference=15,1991.0,CN\C(NCCSCC1=CSC(CN(C)C)=N1)=C\N(=O)=O
Obeticholic Acid,[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)[C@H](CC)[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O,Hepatic steatosis,Human,-1.6989700043360187,Repeated,Oral,"EMA approval document: Assessment Report EMA/725757/2016; EMEA/H/C/004093/0000, page:108 PDF 5361k",https://www.pharmapendium.com/browse/ema/Obeticholic Acid/422df873233a9e9688cb536508125184?reference=108,2016.0,[H][C]1(CC[C]2([H])[C]3([H])[CH](O)[CH](CC)[C]4([H])C[CH](O)CC[C]4(C)[C]3([H])CC[C]12C)[CH](C)CCC(O)=O
Olanzapine,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2,Hepatic steatosis,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Label 020592/S-040, S-041, page:22 PDF 524k",https://www.pharmapendium.com/browse/fda/Olanzapine/123fdf978c5c8f8e5346b56d8750ede2?reference=22,2009.0,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
Omeprazole,COC1=CC=C2NC(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C,Hepatic steatosis,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022032/S-000, page:92 PDF 6854k",https://www.pharmapendium.com/browse/fda/Omeprazole/f6b25703d5175f3e9cf24629ad788b65?reference=92,2006.0,COC1=CC=C2NC(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C
Orlistat,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,Hepatic steatosis,Human,-2.0791812460476247,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021887/S-000 Part 01, page:43 PDF 4480k",https://www.pharmapendium.com/browse/fda/Orlistat/3f97e8190e694a8cb2e2e90a1f1afa61?reference=43,2005.0,CCCCCCCCCCC[CH](C[CH]1OC(=O)[CH]1CCCCCC)OC(=O)[CH](CC(C)C)NC=O
Pantoprazole Sodium,COC1=C(OC)C(=NC=C1)\C=S([O-])\C1=NC2=CC(OC(F)F)=CC=C2N1,Hepatic steatosis,Human,-2.380211241711606,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020987/S-007, page:44 PDF 1373k",https://www.pharmapendium.com/browse/fda/Pantoprazole Sodium/fc792609ea1639d725d409fa83f0f250?reference=44,2002.0,COC1=C(OC)C(=NC=C1)\C=S([O-])\C1=NC2=CC(OC(F)F)=CC=C2N1
Pexidartinib Hydrochloride,FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C34)C=C2)C=N1,Hepatic steatosis,Human,-3.0,Repeated,Oral,"FDA approval package document: Approval Package 211810/S-000 Part 07, page:43 PDF 855k",https://www.pharmapendium.com/browse/fda/Pexidartinib Hydrochloride/b8014b9a95e2f8615062ebf1f04be996?reference=43,2019.0,FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C34)C=C2)C=N1
Pitavastatin Calcium,O[C@H](C[C@H](O)\C=C\C1=C(N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)C1CC1)CC([O-])=O,Hepatic steatosis,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022363/S-000 Part 02, page:29 PDF 7655k",https://www.pharmapendium.com/browse/fda/Pitavastatin Calcium/e8281e4f223086197f54edda5d0b953e?reference=29,2008.0,O[CH](C[CH](O)\C=C\C1=C(N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)C1CC1)CC([O-])=O
Posaconazole,CC[C@@H]([C@H](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@@](C2)(CN2C=NC=N2)C2=C(F)C=C(F)C=C2)C=C1,Hepatic steatosis,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022003/S-000, page:125 PDF 8671k",https://www.pharmapendium.com/browse/fda/Posaconazole/f5037214d79cab10872dcc1e689683b6?reference=125,2005.0,CC[CH]([CH](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[CH]2CO[C](C2)(CN2C=NC=N2)C2=C(F)C=C(F)C=C2)C=C1
Pravastatin Sodium,[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC([O-])=O)OC(=O)[C@@H](C)CC,Hepatic steatosis,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Approval Package 019898/S-050, page:6 PDF 4062k",https://www.pharmapendium.com/browse/fda/Pravastatin Sodium/108a6de2bc9734d7224a77deebc2b034?reference=6,2002.0,[H][C]12[CH](C[CH](O)C=C1C=C[CH](C)[CH]2CC[CH](O)C[CH](O)CC([O-])=O)OC(=O)[CH](C)CC
Pregabalin,CC(C)C[C@H](CN)CC(O)=O,Hepatic steatosis,Human,-2.8195439355418688,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 209501/S-000 Part 07, page:2 PDF 843k",https://www.pharmapendium.com/browse/fda/Pregabalin/9db87ebef7146a359e29373a681a2064?reference=2,2017.0,CC(C)C[CH](CN)CC(O)=O
Rabeprazole Sodium,COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3[N-]2)=NC=C1,Hepatic steatosis,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020973, page:75 PDF 3861k",https://www.pharmapendium.com/browse/fda/Rabeprazole Sodium/cd5324d145f95f7fb7f9add29725eb72?reference=75,1999.0,COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3[N-]2)=NC=C1
Raltegravir Potassium,CN1C(=O)C([O-])=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1,Hepatic steatosis,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022145/S-000 Part 01, page:80 PDF 6696k",https://www.pharmapendium.com/browse/fda/Raltegravir Potassium/af40780e21e1a3c69e5027a0fcf4730c?reference=80,2007.0,CN1C(=O)C([O-])=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1
Risperidone,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1,Hepatic steatosis,Human,-1.6989700043360187,Repeated,Intramuscular,"FDA approval package document: Label 021346/S-013, page:28 PDF 1117k",https://www.pharmapendium.com/browse/fda/Risperidone/0c7946c7391b69ddee75d111e62bc4b5?reference=28,2006.0,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
Rivaroxaban,ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O,Hepatic steatosis,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022406/S-000 Part 01, page:65 PDF 1333k",https://www.pharmapendium.com/browse/fda/Rivaroxaban/bc6e880b062db2c78b661508027015fd?reference=65,2009.0,ClC1=CC=C(S1)C(=O)NC[CH]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O
Ropinirole Hydrochloride,CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2,Hepatic steatosis,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Approval Package 020658/S-013 Part 02, page:34 PDF 8037k",https://www.pharmapendium.com/browse/fda/Ropinirole Hydrochloride/c0b3a423bad73c45743dfe9fe93bfb48?reference=34,2005.0,CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2
Selexipag,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(N=C1)C1=CC=CC=C1,Hepatic steatosis,Human,-3.2041199826559246,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 207947/S-000 Part 05, page:18 PDF 601k",https://www.pharmapendium.com/browse/fda/Selexipag/0a014815d9b037d06801f9864d8abfcb?reference=18,2015.0,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(N=C1)C1=CC=CC=C1
Stavudine,CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O,Hepatic steatosis,Human,-1.6020599913279623,Repeated,Oral,"EMA approval document: ANNEX I, page:7 PDF 3068k",https://www.pharmapendium.com/browse/ema/Stavudine/6ad9975c57fd1d005f31eb302771e254?reference=7,2020.0,CC1=CN([CH]2O[CH](CO)C=C2)C(=O)NC1=O
Sulfadimethoxine,COC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC(OC)=N1,Hepatic steatosis,Human,-3.6989700043360187,Repeated,Oral,"FDA approval package document: Review 011766 Part 05, page:14 PDF 3038k",https://www.pharmapendium.com/browse/fda/Sulfadimethoxine/129b82170dddeddccb03dd9026a116d9?reference=14,1968.0,COC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC(OC)=N1
Tacrolimus,[H][C@]12O[C@](O)([C@H](C)C[C@@H]1OC)C(=O)C(=O)N1CCCC[C@H]1C(=O)O[C@@H]([C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)\C=C(C)\C[C@H](C)C[C@@H]2OC)C(\C)=C\[C@H]1CC[C@@H](O)[C@H](C1)OC,Hepatic steatosis,Human,-1.2304489213782739,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 206406/S-000 Part 02, page:8 PDF 654k",https://www.pharmapendium.com/browse/fda/Tacrolimus/c30840afd922a7b9861d9e52eb63613c?reference=8,2014.0,[H][C]12O[C](O)([CH](C)C[CH]1OC)C(=O)C(=O)N1CCCC[CH]1C(=O)O[CH]([CH](C)[CH](O)CC(=O)[CH](CC=C)\C=C(C)\C[CH](C)C[CH]2OC)C(\C)=C\[CH]1CC[CH](O)[CH](C1)OC
Telbivudine,CC1=CN([C@@H]2C[C@@H](O)[C@H](CO)O2)C(=O)NC1=O,Hepatic steatosis,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022154/S-000 Part 02, page:52 PDF 6048k",https://www.pharmapendium.com/browse/fda/Telbivudine/3503c73eba7bc95acbe717f48fd3a582?reference=52,2009.0,CC1=CN([CH]2C[CH](O)[CH](CO)O2)C(=O)NC1=O
Teriflunomide,C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F,Hepatic steatosis,Human,-1.146128035678238,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 202992/S-000 Part 12, page:90 PDF 11938k",https://www.pharmapendium.com/browse/fda/Teriflunomide/9711c01cf59f491dbbc62266f7c8962f?reference=90,2012.0,C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F
Ticagrelor,CCCSC1=NC(N[C@@H]2C[C@H]2C2=CC=C(F)C(F)=C2)=C2N=NN([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)C2=N1,Hepatic steatosis,Human,-1.7781512503836436,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/18297/2016; EMEA/H/C/001241/0029/G, page:51 PDF 2720k",https://www.pharmapendium.com/browse/ema/Ticagrelor/934524cbaa3f43fa88f07c6ad808e107?reference=51,2015.0,CCCSC1=NC(N[CH]2C[CH]2C2=CC=C(F)C(F)=C2)=C2N=NN([CH]3C[CH](OCCO)[CH](O)[CH]3O)C2=N1
Tipranavir,CCC[C@@]1(CCC2=CC=CC=C2)CC(O)=C([C@H](CC)C2=CC=CC(NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)=C2)C(=O)O1,Hepatic steatosis,Human,-2.6989700043360187,Repeated,Oral,"FDA approval package document: Label 022292/S-000; 021814/S-005, page:8 PDF 781k",https://www.pharmapendium.com/browse/fda/Tipranavir/e64bd5097e32bb239dcfdbb10f33afad?reference=8,2008.0,CCC[C]1(CCC2=CC=CC=C2)CC(O)=C([CH](CC)C2=CC=CC(NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)=C2)C(=O)O1
Topiramate,[H][C@@]12OC(C)(C)O[C@]1(COS(N)(=O)=O)OC[C@H]1OC(C)(C)O[C@@H]21,Hepatic steatosis,Human,-2.0,Repeated,Oral,"FDA approval package document: Approval Package 020505/S-018 Part 10, page:28 PDF 6374k",https://www.pharmapendium.com/browse/fda/Topiramate/c75d7064dfab18b263945d8305d4279f?reference=28,2005.0,[H][C]12OC(C)(C)O[C]1(COS(N)(=O)=O)OC[CH]1OC(C)(C)O[CH]21
Trandolapril,[H][C@]12CCCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC,Hepatic steatosis,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Approval Package 020528/S-001 Part 02, page:14 PDF 1012k",https://www.pharmapendium.com/browse/fda/Trandolapril/281895f55f444bcb4024286951c134cb?reference=14,1996.0,[H][C]12CCCC[C]1([H])N([CH](C2)C(O)=O)C(=O)[CH](C)N[CH](CCC1=CC=CC=C1)C(=O)OCC
Tucatinib,CC1=CC(NC2=C3C=C(NC4=NC(C)(C)CO4)C=CC3=NC=N2)=CC=C1OC1=CC2=NC=NN2C=C1,Hepatic steatosis,Human,-2.4771212547196626,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/78409/2021; EMEA/H/C/005263/0000, page:115 PDF 7669k",https://www.pharmapendium.com/browse/ema/Tucatinib/9853a892aaf187403450ff694ca2cbcd?reference=115,2020.0,CC1=CC(NC2=C3C=C(NC4=NC(C)(C)CO4)C=CC3=NC=N2)=CC=C1OC1=CC2=NC=NN2C=C1
Upadacitinib,CC[C@@H]1CN(C[C@@H]1C1=CN=C2C=NC3=C(C=CN3)N12)C(=O)NCC(F)(F)F,Hepatic steatosis,Human,-1.1760912590556813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 211675/S-000 Part 05, page:7 PDF 751k",https://www.pharmapendium.com/browse/fda/Upadacitinib/3c6ce3b9a18f071202ec95401c9d4de8?reference=7,2019.0,CC[CH]1CN(C[CH]1C1=CN=C2C=NC3=C(C=CN3)N12)C(=O)NCC(F)(F)F
Venlafaxine Hydrochloride,COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1,Hepatic steatosis,Human,-2.574031267727719,Repeated,Oral,"FDA approval package document: Approval Package 076565/S-000 Part 01, page:12 PDF 430k",https://www.pharmapendium.com/browse/fda/Venlafaxine Hydrochloride/5cd234a6c0473f68efdb6f0cc83b8642?reference=12,2010.0,COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1
Zidovudine,CC1=CN([C@H]2C[C@H](N=N#N)[C@@H](CO)O2)C(=O)NC1=O,Hepatic steatosis,Human,-2.6989700043360187,Repeated,Oral,"FDA approval package document: Label 022294/S-000, page:10 PDF 1706k",https://www.pharmapendium.com/browse/fda/Zidovudine/70ff07f13b40ebc73f6eb329d66c9777?reference=10,2009.0,CC1=CN([CH]2C[CH](N=N#N)[CH](CO)O2)C(=O)NC1=O
Ziprasidone Hydrochloride,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=CC=CC=C12,Hepatic steatosis,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 020825/S-021; 020919/S-012, page:29 PDF 4127k",https://www.pharmapendium.com/browse/fda/Ziprasidone Hydrochloride/7d8ee6172d21b6fea5f9a04021d4e70e?reference=29,2007.0,ClC1=CC2=C(CC(=O)N2)C=C1CCN1CCN(CC1)C1=NSC2=CC=CC=C12
